Skip to Content

Arkema SA

AKE: XPAR (FRA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
€653.00PfdjWjcgrmmks

Arkema Earnings: EBITDA Results Beat Consensus Across All Segments

No-moat Arkema reported first-quarter EBITDA of EUR 367 million, down 41% compared with the exceptionally high comparison base of 2022 in upstream acrylics and PVDF, but around 9% above the company’s compiled consensus. Arkema confirmed its guidance for the year and aims to achieve EBITDA of around EUR 1.5 billion to EUR 1.6 billion and maintain a high EBITDA to cash conversion rate of over 40%. Shares rose 4% intraday. We don’t expect to make a material change to our EUR 105 fair value estimate. At current levels, the shares are trading in 4-star territory.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of AKE so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center